Spoilt for choice

Graham Kelly must be at his wit's end, having to decide which of a plethora of opportunities Noxopharm should pursue.

Since NOX listed on the ASX in August 2016, he has discovered that:

1.  A compassionate patient suffering from sarcoma and lung cancer is doing remarkably well after 30 months.  To be fair this should have come as no surprise, because GK is FREE of cancer after five years, but what would he know?
2.  Patients in the LuPIN trial were so sick that a high proportion dropped out of the trial between enrolment and the first injection, and yet treatment of the others with LuPSMA plus Veyonda led to durable responses that greatly exceeded anything achieved by LuPSMA alone.  A nit-picker might suggest this is irrelevant because Novartis has problems of its own, but the performance of Veyonda as an enhancer of one radionuclide suggests that it would also improve the performance of other radionuclides - of which there are many.  This is an easy one to discard, because Harvett has decided it will never happen.   
3.  When Veyonda was combined with low-dose chemotherapy in late stage patients, good results were achieved but without the usual side effects.  But those patients were treated in Georgia, perhaps they fudged the results?
4.  When Veyonda was used with low-dose external radiation a high proportion of patients achieved durable responses.  The problem is that treatment is quick, does not require admission to a hospital, can be safely repeated, gets the immune system to help, and offers hope to terminally-ill patients.  Sounds too good, so discard that one as well?
5.  In the LuPIN and DARRT trials, PSA continued to decline well after treatment had finished, suggesting that the immune system had been re-activated.  Probably another fluke.
6.  Noxopharm says it has evidence that Veyonda is a STING agonist, able to reactivate the dormant immune system, generate abscopal response and which could overcome shortcomings of Check Point Inhibitors.  Sounds like another loser.
7.  Nyrada has used world-renowned collaborators to help develop promising non-oncology drugs that are nearing the clinic.  Again, what would they know?

I think GK should ignore these developments and stick with the program published some time ago, even if a change would lead to faster approval and therefore enable oncologists to use Veyonda off-label in each of these indications.  Then again, perhaps Graham does know what he is doing.